GoAI
Get started
BrainAurora Medical Technology Limited logo

BrainAurora Medical Technology Limited

6681.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$1.505

−HK$0.02 · -1.31%

Aug 24, 4:08 PM HKT

6681.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the evaluation and intervention of cognitive impairments to treat vascular diseases, neurodegenerative diseases, psychological disorders, and child development deficiencies. The company develops the Brain Function Information Management Platform software system, an evidence-based, medical-grade DTx product; Basic Cognitive Testing Software, an assessment of patients for basic cognitive capacity; Cognitive Ability Supplemental screening and assessment software, a solution designed to facilitate healthcare professionals assessment of patients; and Dyslexia Supplemental Screening and Assessment Software, a solution designed to facilitate the assessment of risk of developmental dyslexia in children. It also develops covid-19 induced cognitive impairment assessment and recovery training software; ADHD assessment and treatment software; quantitative cognitive assessment software for depression; depression treatment software; and cognitive impairment assessment software and cognitive impairment treatment software solutions. In addition, the company provides marketing services. BrainAurora Medical Technology Limited was founded in 2012 and is headquartered in Shaoxing, China.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Long Jun Cai
Listed since
Jan 8, 2025
Employees
165

Market position

Day range

Current HK$1.505

52-week range

Current HK$1.505

Open
HK$1.55
Previous close
HK$1.525
Volume
5.26M
0.18× average
Average volume
29.84M
Average daily volume
Market cap
2.04B HKD
Beta
1.99
Market reference 1
50-day average
HK$1.7363
-13.32% below average
200-day average
HK$4.089
-63.19% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
6.98B CNY
P/E (TTM)
-4.83×
P/B (TTM)
15.64×
P/S (TTM)
7.97×
EV / EBITDA
-25.25×
Earnings yield
-4.67%
Free cash flow yield
-3.05%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
40.65%
Operating margin
-132.22%
Net margin
-143.09%
Return on equity
-323.31%
Return on assets
-42.94%
Return on invested capital
-43.90%

Financial health

Debt / equity
5.81×
Current ratio
1.56×
Altman Z-score
-3.13
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3098%-9066%-21231%-33395%Gross margin, FY2021: 56.72%Gross margin, FY2022: 29.20%Gross margin, FY2023: 47.71%Gross margin, FY2024: 44.16%Gross margin, FY2025: 40.65%Operating margin, FY2021: -3007.61%Operating margin, FY2022: -923.88%Operating margin, FY2023: -217.16%Operating margin, FY2024: -140.85%Operating margin, FY2025: -132.22%Net margin, FY2021: -30353.94%Net margin, FY2022: -4450.02%Net margin, FY2023: -534.35%Net margin, FY2024: -162.11%Net margin, FY2025: -143.09%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 56.72%. Gross margin FY2022 29.20%. Gross margin FY2023 47.71%. Gross margin FY2024 44.16%. Gross margin FY2025 40.65%. Operating margin FY2021 -3007.61%. Operating margin FY2022 -923.88%. Operating margin FY2023 -217.16%. Operating margin FY2024 -140.85%. Operating margin FY2025 -132.22%. Net margin FY2021 -30353.94%. Net margin FY2022 -4450.02%. Net margin FY2023 -534.35%. Net margin FY2024 -162.11%. Net margin FY2025 -143.09%.

Income trends

Revenue

220.05M CNY+79.91%

Operating income

−290.95M CNY-68.89%

Net income

−314.86M CNY-58.79%
Income trends across reported periods311.84M CNY−55.32M CNY−422.47M CNY−789.63M CNYRevenue, FY2021: 2.3M CNYRevenue, FY2022: 11.29M CNYRevenue, FY2023: 67.2M CNYRevenue, FY2024: 122.31M CNYRevenue, FY2025: 220.05M CNYOperating income, FY2021: −69.15M CNYOperating income, FY2022: −104.32M CNYOperating income, FY2023: −145.93M CNYOperating income, FY2024: −172.27M CNYOperating income, FY2025: −290.95M CNYNet income, FY2021: −697.84M CNYNet income, FY2022: −502.45M CNYNet income, FY2023: −359.08M CNYNet income, FY2024: −198.28M CNYNet income, FY2025: −314.86M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.3M CNY. Revenue FY2022 11.29M CNY. Revenue FY2023 67.2M CNY. Revenue FY2024 122.31M CNY. Revenue FY2025 220.05M CNY. Operating income FY2021 −69.15M CNY. Operating income FY2022 −104.32M CNY. Operating income FY2023 −145.93M CNY. Operating income FY2024 −172.27M CNY. Operating income FY2025 −290.95M CNY. Net income FY2021 −697.84M CNY. Net income FY2022 −502.45M CNY. Net income FY2023 −359.08M CNY. Net income FY2024 −198.28M CNY. Net income FY2025 −314.86M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue220.05M CNY122.31M CNY67.2M CNY11.29M CNY2.3M CNY
Cost of goods sold130.6M CNY68.3M CNY35.14M CNY7.99M CNY995K CNY
Gross profit89.45M CNY54.01M CNY32.06M CNY3.3M CNY1.3M CNY
Research and development165.9M CNY119.42M CNY90.73M CNY67.63M CNY32.76M CNY
Selling, general, and administrative175.58M CNY107.94M CNY88.12M CNY15.83M CNY11.45M CNY
Operating expenses380.41M CNY226.28M CNY178M CNY107.61M CNY70.45M CNY
Interest income13.65M CNY627K CNY2.08M CNY3.9M CNY1.33M CNY
Interest expense23.99M CNY22.03M CNY20.22M CNY19.22M CNY6.39M CNY
Depreciation and amortization14.27M CNY17.55M CNY21.27M CNY12.43M CNY1.63M CNY
Operating income−290.95M CNY−172.27M CNY−145.93M CNY−104.32M CNY−69.15M CNY
Net income−314.86M CNY−198.28M CNY−359.08M CNY−502.45M CNY−697.84M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.09

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.05-0.09-0.12-0.16Q1 '25Q3 '25Q1 '26
Q1 2025, reported Mar 28, 2025: actual -0.058, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 28, 2025: actual -0.12, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 25, 2026: actual -0.089, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates113.83M92.19M70.55M48.91MQ1 '25Q3 '25Q1 '26
Q1 2025, reported Mar 28, 2025: actual 53.38M HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 28, 2025: actual 109.35M HKD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 25, 2026: actual 66.73M HKD, estimate —, surprise —, Comparison unavailable.

6681.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 6681.HK

research.disclaimer